The Diagnostics & Lab Testing Business Brief — Friday, November 13, 2026
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Summary
The Diagnostics & Lab Testing Business Brief — Friday, November 13, 2026
- CMS finalizes moving stand-alone algorithmic analyses performed on laboratory tests off the Clinical Laboratory Fee Schedule for CY2027, paying them as “other diagnostic tests” under OPPS at New Technology APC rates aligned with CY2026 CLFS rates — a classification change raising industry concerns and uncertainty. (GenomeWeb; CMS)
- Lucid Diagnostics Q3 2026: 2,871 EsoGuard tests performed and $1.2 million in revenue, a record 1,800+ tests in October after first Medicare payments at $1,938.01 per test, and a $15 million financing closed after the quarter. (PR Newswire)
- PAVmed update: Veris Health achieves design freeze for its implantable physiological monitor and begins a 90-day GLP animal study, on track for an early 2027 FDA 510(k) submission. (PR Newswire)
- Naitive receives FDA 510(k) clearance for OsteoSight Spine, extending AI-enabled opportunistic bone mineral density assessment to routine lumbar spine, thoracic spine, and chest X-rays in patients 50 and older. (Orthopedics This Week)
- Bluejay Diagnostics completes SYMON-II enrollment with 777 evaluable patients for its Symphony IL-6 sepsis test and targets an FDA 510(k) submission in the first half of 2027; the test is not yet FDA cleared or approved. (ACCESS Newswire)
- Proto360 Health integrates Phenomix Sciences' MyPhenome genetic obesity test into its employer metabolic care program, making it part of the diagnostic assessment before a GLP-1 prescribing decision. (PR Newswire)
- BCAL Diagnostics (18.46% shareholder) applies to Australia's Takeovers Panel over Genetic Signatures' proposed Microba merger, under which Microba shareholders would own 60% of the combined group; the Panel has made no decision. (TipRanks)
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.